FGF2 and COVID-19: The COVID-19 group had significantly higher plasma levels of IL-1β, IL-4, IL-7, IL-8, IL-12, TNF, IP-10, eotaxin, GM-CSF, bFGF, and the complement activation products TCC and C3bc, as compared to the non-COVID-19 group (Table 2).